Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

about

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

Item

http://www.wikidata.org/entity/Q55481165

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@en

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@nl

type

Item

label

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@en

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@nl

prefLabel

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@en

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@nl

P1476

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.

@en

P2093

Heleen Vroman

http://www.w3.org/2001/XMLSchema#string

Joachim Aerts

http://www.w3.org/2001/XMLSchema#string

Jorien Minnema-Luiting

http://www.w3.org/2001/XMLSchema#string

Robin Cornelissen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Malignant mesothelioma: facts, myths, and hypotheses

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Pathology of malignant mesothelioma.

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.

P31

scholarly article

review article

P356

10.3390/IJMS19041041

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29601534

http://www.w3.org/2001/XMLSchema#string

P921

mesothelioma

pleural cancer

lung cancer

P932

5979422

http://www.w3.org/2001/XMLSchema#string